地中海饮食对银屑病患者的影响:MEDIPSO随机临床试验
MEDIPSO为开放标签、单中心、评估者单盲随机临床试验,纳入38例接受稳定外用治疗的轻中度银屑病成人患者,1:1分为16周地中海饮食干预组与对照组。第16周干预组PASI估计边际均值变化为-3.4,组间差异-3.4(95%CI -4.8至-2.0;P<.001),并观察到HbA1c显著下降。
要点
- 16周地中海饮食干预可显著降低轻中度银屑病患者PASI。
- 干预组19例中9例(47.4%)达PASI 75,对照组无。
- 干预组HbA1c较对照组显著下降,提示代谢获益。
核心结论
- 16周地中海饮食干预显著改善接受稳定外用治疗的轻中度银屑病患者的疾病严重程度。
- 研究提示饮食策略可作为银屑病管理的辅助治疗。
研究设计与样本
- 开放标签、单中心、评估者单盲随机临床试验,2024年2月至2025年3月在西班牙马德里皮肤科转诊门诊开展。
- 筛查45人,纳入并随机38例轻中度银屑病成人(PASI 2-10,接受稳定外用治疗),干预组19例、对照组19例。
- 平均(SD)年龄46.4(12.8)岁,男性25例(65.8%),37例(97.4%)完成研究。
主要发现
- 第16周PASI估计边际均值变化:干预组-3.4(95%CI -4.4至-2.4),对照组0.0(95%CI -1.0至1.0)。
- 组间估计边际均值差异为-3.4(95%CI -4.8至-2.0;P<.001)。
- 干预组19例中9例(47.4%)达到PASI 75,对照组无一例达到。
关键数值与推荐
- 干预组与对照组HbA1c的组间估计边际均值差异为-4.1 mmol/mol(95%CI -6.9至-1.3 mmol/mol;P=.01)。
- 干预为16周营养师指导的地中海饮食方案,含营养咨询、教育材料及每周提供特级初榨橄榄油。
- 对照组接受常规低脂饮食建议,无营养师监督。
临床怎么用
- 对接受稳定外用治疗的轻中度银屑病患者,可考虑将地中海饮食作为辅助管理策略。
- 干预需营养师指导并保证特级初榨橄榄油供应,同时关注代谢指标如HbA1c。
局限性
- 样本量小(38例),为单中心开放标签设计,仅评估者设盲。
- 干预期仅16周,未报告长期维持与复发数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite growing interest on the role of diet in the prevention and treatment of psoriasis, randomized clinical trials are lacking. The Mediterranean diet is known for its anti-inflammatory and cardiometabolic benefits, which may be relevant to psoriasis pathophysiology. OBJECTIVE: To assess whether a 16-week Mediterranean diet intervention would improve psoriasis severity in patients with mild to moderate disease. DESIGN, SETTING, AND PARTICIPANTS: MEDIPSO (Impact of the Mediterranean Diet on Patients With Psoriasis), an open-label, single-center, single-blinded (evaluator) randomized clinical trial, was conducted from February 2024 to March 2025 at a dermatology referral clinic in Madrid, Spain. Participants were adults with mild to moderate psoriasis (Psoriasis Area and Severity Index [PASI] of 2-10, with higher scores indicating maximal disease) receiving stable topical therapy. INTERVENTIONS: Participants were randomized 1:1 to the intervention or control group. The intervention group received a 16-week, dietitian-guided Mediterranean diet program, including nutritional counseling, educational materials, and weekly provision of extra virgin olive oil. The control group received standard low-fat dietary advice without dietitian supervision. MAIN OUTCOMES AND MEASURES: The primary outcome was the change in the PASI from baseline to week 16. Secondary outcomes included changes in Mediterranean diet adherence, anthropometric and metabolic parameters, serum inflammatory cytokines, and patient-reported outcomes. Estimated marginal means (EMMs) at baseline and for the change from baseline to week 16 were reported, with the intervention effect presented as the between-group difference. RESULTS: Among 45 individuals screened, 38 participants were enrolled and randomized (mean [SD] age, 46.4 [12.8] years; 25 males [65.8%]); 19 were randomized to the intervention group and 19 were randomized to the control group; 37 individuals (97.4%) completed the study. The EMM PASI change at week 16 was -3.4 (95% CI, -4.4 to -2.4) in the intervention group and 0.0 (95% CI, -1.0 to 1.0) in the control group; the between-group EMM difference was -3.4 (95% CI, -4.8 to -2.0; P < .001). Nine of 19 participants in the Mediterranean diet group (47.4%) achieved PASI 75 (a 75% reduction in PASI) compared with none in the control group. A significant reduction in EMM hemoglobin A1c (glycated hemoglobin) was observed in the intervention group as compared with the control group (between-group EMM difference, -4.1 mmol/mol [95% CI, -6.9 to -1.3 mmol/mol]; P = .01). CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that a 16-week Mediterranean diet intervention significantly improved psoriasis severity in patients with mild to moderate disease receiving stable topical therapy. These findings suggest that incorporating dietary strategies may be beneficial as an adjunctive therapy in psoriasis management. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06257641.
引用
- Perez-Bootello J, Berna-Rico E, Abbad-Jaime de Aragon C, et al. Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40991259. doi:10.1001/jamadermatol.2025.3410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。